Elite Pharmaceuticals (OTCQB: ELTP) has received FDA approval for its generic version of Vyvanse (Lisdexamfetamine Dimesylate) capsules in seven different strengths ranging from 10 mg to 70 mg. The medication is designed to treat Attention Deficit Hyperactivity Disorder (ADHD). According to IQVIA data, the combined brand and generic market for this product recorded annual sales of $4.3 billion for the twelve months ending September 2024.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.